EUVIMEDEUVIMED entdecken
Open Access

In vivo functional profiling and structural characterization of the human GLP1R A316T variant

Liliane El Eid iD, Yusman Manchanda iD, Gregory Austin, Kieran Deane-Alder iD, Roxana-Maria Rujan iD, Zamara Mariam, Affiong I Oqua iD, Matthew J Belousoff iD, Jorge Bernardino de la Serna iD, Kyle W Sloop iD, Guy A Rutter iD, Alex Montoya iD und 9 weitere

Science Advances · 06.02.2026 · 12 (6)

DOI: 10.1126/sciadv.adw0899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 06.02.2026. Verfasst von Liliane El Eid und 20 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduc…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Diabetes UK, Society for Endocrinology, MRC-PHE Centre for Environment and Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective therapies for type 2 diabetes (T2D) and obesity, yet patient responses are variable, with GLP1R gene variation potentially linked to therapeutic outcomes. A GLP1R natural missense variant, A316T, protects against T2D and cardiovascular disease. Here, we generated and characterized a human GLP1R A316T mouse model. Human GLP1R A316T/A316T mice displayed lower fasting blood glucose versus wild-type littermates even under metabolic stress, as well as slower weight gain and alterations in islet cytoarchitecture, glucagon secretion, and liver metabolism under a high-fat, high-sucrose diet. This was however associated with blunted responses to pharmacological GLP-1RAs in vivo. Further investigations in β cell models demonstrated that human GLP1R A316T exhibits characteristics of constitutive activation but dampened GLP-1RA responses. Results are further supported by cryo-EM analyses and molecular dynamics simulations of GLP-1R A316T structure, collectively demonstrating that the A316T variant governs basal GLP-1R activity and pharmacological responses to GLP-1R–targeting therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorHumansAnimalsMiceDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsMolecular Dynamics SimulationInsulin-Secreting CellsProtein ConformationBlood GlucoseMutation, MissenseDisease Models, AnimalHomeostasis

Substanzen

GLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsBlood Glucose

Autor:innen und Institutionen

  • Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • ARC Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Centre for Health and Life Sciences, Coventry University, Coventry, UK.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

ORCID-Profile: Liliane El Eid, Yusman Manchanda, Kieran Deane-Alder, Roxana-Maria Rujan, Affiong I Oqua, Matthew J Belousoff, Jorge Bernardino de la Serna, Kyle W Sloop, Guy A Rutter, Alex Montoya, Dominic J Withers, Steven J Millership, Karim Bouzakri, Ben Jones, Christopher A Reynolds, Patrick M Sexton, Denise Wootten, Giuseppe Deganutti, Alejandra Tomas

Förderung

  • Diabetes UK
  • Society for Endocrinology
  • MRC-PHE Centre for Environment and Health
  • BBSRC
  • MRC Programme Grant
  • NIH-NIDDK
  • National Health and Medical Research Council
  • NHMRC Ideas

Zitieren

APA

El Eid, L., Manchanda, Y., Austin, G., Deane-Alder, K., Rujan, R. M., Mariam, Z., Oqua, A. I., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., Rutter, G. A., Montoya, A., Withers, D. J., Millership, S. J., Bouzakri, K., Jones, B., Reynolds, C. A., Sexton, P. M., Wootten, D., …, & Tomas, A. (2026). In vivo functional profiling and structural characterization of the human GLP1R A316T variant. Science Advances, 12(6). https://doi.org/10.1126/sciadv.adw0899

Vancouver

El Eid L, Manchanda Y, Austin G, Deane-Alder K, Rujan RM, Mariam Z, et al. In vivo functional profiling and structural characterization of the human GLP1R A316T variant. Science Advances. 2026;12(6). doi:10.1126/sciadv.adw0899

BibTeX
@article{ElEid2026,
  author = {El Eid, Liliane and Manchanda, Yusman and Austin, Gregory and Deane-Alder, Kieran and Rujan, Roxana-Maria and Mariam, Zamara and Oqua, Affiong I and Belousoff, Matthew J and de la Serna, Jorge Bernardino and Sloop, Kyle W and Rutter, Guy A and Montoya, Alex and Withers, Dominic J and Millership, Steven J and Bouzakri, Karim and Jones, Ben and Reynolds, Christopher A and Sexton, Patrick M and Wootten, Denise and Deganutti, Giuseppe and Tomas, Alejandra},
  title = {In vivo functional profiling and structural characterization of the human GLP1R A316T variant},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {6},
  doi = {10.1126/sciadv.adw0899}
}
Kostenlos starten →